测试NON-STOP应用程序的可用性和可接受性,用于患有珀斯病的儿童
Adam M Galloway1,2, David J Keene3, Kerry Cleary2,4
1Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Bone & joint open
|January 12, 2026
概括
非停止应用程序是一个可用的和可接受的数字工具,用于儿童与珀斯病,改善自我管理. 这项研究为一项大型临床试验准备了应用程序,该试验比较了手术和非手术治疗.
科学领域:
- 儿科整形外科 儿科整形外科
- 数字健康干预措施 数字健康干预措施
- 医疗保健服务研究 医疗服务研究
背景情况:
- 珀斯病是一种儿童部疾病,需要广泛管理.
- 家庭和临床医生需要为儿科患者提供更好的自我管理工具.
- 这款NON-STOP应用程序是为了支持患有珀斯病的儿童而开发的.
研究的目的:
- 评估NON-STOP数字自我管理应用程序的可用性和可接受性.
- 收集用于最终临床试验的初步数据.
- 根据用户反来改进应用程序.
主要方法:
- 混合方法研究,包括观察性前后设计和重点小组.
- 31名患有珀斯病的儿童使用了NON-STOP应用程序六周.
- 收集的数据包括应用程序的参与度,可用性 (Health ITUES),生活质量和体育活动.
主要成果:
- 这款NON-STOP应用程序在用户中表现出高度的可用性和可接受性.
- 应用程序的参与度在最初几周是最高的,随后下降.
- 用户发现该应用程序比传统方法更具吸引力,欣赏奖励和化身.
结论:
- 无止境应用程序是一个可行的和受欢迎的工具,用于儿科珀斯病的自我管理.
- 用户反指导了应用程序的改进,以实现未来的临床整合.
- 这些发现支持该应用程序在即将到来的Op NON-STOP试验中使用.
相关概念视频
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...


